Previous Article | Next Article ![]()
J. Virol., 07 1996, 4523-4529, Vol 70, No. 7
O Hammarsten, X Yao and P Elias
Cellular topoisomerase II is specifically inactivated by the drug ICRF-
193. This compound turns topoisomerase II into a closed clamp that is
unable to cleave DNA. We have investigated the effects of this inhibitor on
the replication of herpes simplex virus type 1. We show that ICRF-193 at
low multiplicities of infection dramatically inhibits viral DNA synthesis
and the production of infectious virus. The inhibition is less efficient at
high multiplicities of infection. In addition, inhibition of viral DNA
synthesis was observed only when ICRF- 193 was present during the first 4 h
of the infectious cycle. The transient replication of plasmids containing a
herpes simplex virus type 1 origin of DNA replication, oriS, was affected
by ICRF-193 in the same way. In contrast, neither cellular DNA synthesis
nor replication of plasmids containing a simian virus 40 origin of DNA
replication was inhibited. The observed effect on herpes simplex virus DNA
replication was not caused by a decreased transcription of replication
genes inasmuch as the levels of UL8, UL9, UL29, and UL30 rmRNAs were
unaffected by the drug. These results suggest that topoisomerase II plays a
vital role during the replication of herpes simplex virus type 1 DNA. We
speculate that topoisomerase II is involved in the decatenation of newly
synthesized daughter molecules.
Copyright © 1996, American Society for Microbiology
Inhibition of topoisomerase II by ICRF-193 prevents efficient replication of herpes simplex virus type 1
Department of Medical Biochemistry, University of Goteborg, Sweden.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|